Mesoblast (NASDAQ:MESO) Stock Price Crosses Below Fifty Day Moving Average – What’s Next?

Shares of Mesoblast Limited (NASDAQ:MESO) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $15.03 and traded as low as $14.45. Mesoblast shares last traded at $14.76, with a volume of 231,972 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Mesoblast Stock Performance

The stock has a market cap of $1.91 billion, a PE ratio of -27.33 and a beta of 2.09. The firm’s 50-day moving average is $15.03 and its 200 day moving average is $16.41. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) EPS for the quarter. The business had revenue of $25.67 million for the quarter. As a group, research analysts anticipate that Mesoblast Limited will post -0.49 EPS for the current year.

Insider Transactions at Mesoblast

In related news, Director Gregory George acquired 4,000,000 shares of Mesoblast stock in a transaction on Saturday, April 4th. The stock was purchased at an average cost of $1.42 per share, with a total value of $5,680,000.00. Following the purchase, the director directly owned 12,000,000 shares in the company, valued at approximately $17,040,000. The trade was a 50.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders bought 9,892,852 shares of company stock valued at $28,429,183. Insiders own 18.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MESO. Legal & General Group Plc lifted its holdings in shares of Mesoblast by 4.2% during the fourth quarter. Legal & General Group Plc now owns 679,023 shares of the company’s stock worth $12,237,000 after purchasing an additional 27,607 shares during the period. Goldman Sachs Group Inc. purchased a new position in Mesoblast during the 1st quarter worth $3,209,000. Bank of America Corp DE lifted its stake in shares of Mesoblast by 791.7% in the 3rd quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock worth $1,796,000 after acquiring an additional 98,960 shares during the period. Rialto Wealth Management LLC purchased a new stake in shares of Mesoblast in the fourth quarter valued at about $839,000. Finally, Brooklyn Investment Group acquired a new position in shares of Mesoblast during the third quarter worth about $655,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.